Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C14H15ClN6O
CAS Number:
Molecular Weight:
318.76
MDL number:
NACRES:
NA.21
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
General description
BIIB021 is a purine scaffold-based second-generation heat shock protein 90 (Hsp90) inhibitor.
Application
BIIB021 may be used to study its effect on growth of natural killer (NK) cells and T cell lymphomas.
Biochem/physiol Actions
BIIB021 (CNF2024) is an orally active, potent and selective heat shock protein 90 (Hsp90) inhibitor that targets the ATP site of Hsp90 (Ki = 1.7 nM against 2 nM FITC-geldanamycin in competitive binding for 0.8 nM rhHsp90α), but not those of 20 cellular kinases or Na+/K+ ATPase. BIIB021 induces Her-2 degradation in MCF7 cells (IC50 = 38 nM post 16h incubation) and exhibits anti-cancer efficacy in cultures (IC50 = 60-310 nM among 8 cancer lines) and in mice in vivo (51-94% tumor growth inhibition among 6 human tumor models; 75-125 mg/kg/d 5x per wk for 5 wks).
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Srinivas R Kasibhatla et al.
Journal of medicinal chemistry, 50(12), 2767-2778 (2007-05-10)
Heat shock protein 90 (Hsp90) is a molecular chaperone protein implicated in stabilizing the conformation and maintaining the function of many cell-signaling proteins. Many oncogenic proteins are more dependent on Hsp90 in maintaining their conformation, stability, and maturation than their
Karen Lundgren et al.
Molecular cancer therapeutics, 8(4), 921-929 (2009-04-18)
Inhibition of heat shock protein 90 (Hsp90) results in the degradation of oncoproteins that drive malignant progression, inducing cell death, making Hsp90 a target of substantial interest for cancer therapy. BIIB021 is a novel, fully synthetic inhibitor of Hsp90 that
Boris Böll et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(16), 5108-5116 (2009-08-13)
In Hodgkin's lymphoma, constitutive activation of NF-kappaB promotes tumor cell survival and proliferation. The molecular chaperone heat shock protein 90 (HSP90) has immune regulatory activity and supports the activation of NF-kappaB in Hodgkin's lymphoma cells. We analyzed the effect of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service